ENLV vs. VIGL, BMEA, ADVM, THTX, ZURA, GNLX, ENTX, AVTE, ADAG, and TCRX
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Vigil Neuroscience (VIGL), Biomea Fusion (BMEA), Adverum Biotechnologies (ADVM), Theratechnologies (THTX), Zura Bio (ZURA), Genelux (GNLX), Entera Bio (ENTX), Aerovate Therapeutics (AVTE), Adagene (ADAG), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.
Enlivex Therapeutics vs.
Enlivex Therapeutics (NASDAQ:ENLV) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
Enlivex Therapeutics received 26 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 84.62% of users gave Vigil Neuroscience an outperform vote while only 80.82% of users gave Enlivex Therapeutics an outperform vote.
Enlivex Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 1,014.21%. Vigil Neuroscience has a consensus price target of $16.25, indicating a potential upside of 990.60%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than Vigil Neuroscience.
Enlivex Therapeutics' return on equity of -67.57% beat Vigil Neuroscience's return on equity.
1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 33.0% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.
Enlivex Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
In the previous week, Enlivex Therapeutics had 1 more articles in the media than Vigil Neuroscience. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 1.82 beat Enlivex Therapeutics' score of 1.42 indicating that Vigil Neuroscience is being referred to more favorably in the news media.
Summary
Enlivex Therapeutics beats Vigil Neuroscience on 9 of the 16 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ENLV) was last updated on 4/14/2025 by MarketBeat.com Staff
Buy ENLV Stock Free ENLV Stock Alerts